The global vulvar cancer market is expected to witness significant growth over the forecast period. The market was valued at approximately USD 681.85 million in 2018 and is projected to register a 6.2% CAGR over the forecast period.
Vulvar cancers occur on the outer surface of the female genitalia and form a lump or a sore on the vulva that might cause itching in the region.
Factors such as the rising prevalence of vulvar cancer are expected to drive market growth. According to an article published by the American Society of Clinical Oncology in March 2019, an estimated 6,070 women in the US were diagnosed with vulvar cancer. Moreover, increasing research and development expenditure in the field of oncology is also expected to boost market growth.
However, the side effects of the treatment are expected to hamper the market growth.
The global vulvar cancer market has been segmented into cancer type, treatment type, end user, and region.
Based on cancer type, the global vulvar cancer market has been segmented into vulvar squamous cell carcinoma, vulvar melanoma, adenocarcinoma, and basal cell carcinoma.
The global vulvar cancer market, by treatment type, has been segmented into chemotherapy, surgery, radiation therapy, and biologic therapy. The surgery segment is further classified into laser surgery, excision, skinning vulvectomy, and radical vulvectomy.
The global vulvar cancer market, by end user, has been segmented into hospitals & clinics, research & academic institutes, and others.
Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Sanofi (France), and Johnson & Johnson Services, Inc. (US) are some of the key players operating in the global vulvar cancer market.
Global Vulvar Cancer Market, by Cancer Type
Global Vulvar Cancer Market, by Treatment Type
Global Vulvar Cancer Market, by End User